Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes), and Region 2024-2032

Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A5973
Buy Now

Market Overview:

The global plasma fractionation market size reached US$ 25.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 25.1 Billion
Market Forecast in 2032
US$ 39.7 Billion
Market Growth Rate 2024-2032 5.1%


Plasma fractionation refers to the downstream processing of donated plasma into life-saving therapies and medicinal products. It breaks plasma into individual proteins or plasma fractions using mechanical separation methods, such as centrifugation, depth filtration, precipitation, and chromatography. Nowadays, several modern fractionation processes use alcohol concentrations, time, temperature, and pH to extract specific therapeutic proteins. Moreover, increasing technology complexity over the years and the introduction of in-process viral reduction treatments have resulted in the development of new protein therapeutics and improvement in product purity and quality.

Global Plasma Fractionation Market Report

Plasma Fractionation Market Trends:

Protein products fractionated from human plasma are an essential class of therapeutics widely used to prevent, manage, and treat life-threatening conditions, such as infections, congenital deficiencies, rare blood disorders, immunologic disorders, and autoimmune disorders. A significant rise in the prevalence of these conditions among a significant part of the population globally represents one of the key factors impelling the market growth. In addition, manufacturers are developing plasma fractionation with additional safety features due to the implementation of stringent regulations and standard controls and settings by governing agencies of numerous countries on quality assurance of biological products. Apart from this, market players are financing research and development (R&D) activities to launch advancement in plasma production technology to improve product efficacy and enhance recovery of immunoglobulin G (IgG) to isolate new plasma proteins. Furthermore, they are focusing on developing affordable viral inactivation and processing technologies that allow utilization of local plasma resources safely. This, in confluence with the escalating need to improve yield, maintain process economics, and manage increasing regulatory requirements, is anticipated to provide a favorable market outlook in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global plasma fractionation market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, sector, application and end user.

Breakup by Product:

  • Immunoglobulins
  • Albumin
  • Coagulation factor VIII
  • Coagulation factor IX
     

Breakup by Sector:

  • Private Sector
  • Public Sector
     

Breakup by Application:

  • Neurology
  • Immunology
  • Hematology
  • Other Applications
     

Breakup by End User:

  • Hospitals and Clinics
  • Clinical Research Laboratories
  • Academic Institutes
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Product, Sector, Application, End User, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global plasma fractionation market was valued at US$ 25.1 Billion in 2023.

We expect the global plasma fractionation market to exhibit a CAGR of 5.1% during 2024-2032.

The sudden outbreak of the COVID-19 pandemic has led to the growing requirement for plasma fractionation to downstream processing of donated plasma for treating the coronavirus-infected patients.

The rising adoption of plasma fractionation to prevent, manage, and treat life-threatening conditions, such as infections, congenital deficiencies, rare blood disorders, etc., is primarily driving the global plasma fractionation market.

Based on the product, the global plasma fractionation market has been divided into immunoglobulins, albumin, coagulation factor VIII, and coagulation factor IX. Among these, immunoglobulins currently exhibit a clear dominance in the market.

Based on the sector, the global plasma fractionation market can be categorized into private sector and public sector. Currently, the private sector accounts for the majority of the total market share.

Based on the application, the global plasma fractionation market has been segregated into neurology, immunology, hematology, and other applications, where neurology currently holds the largest market share.

Based on the end user, the global plasma fractionation market can be bifurcated into hospitals and clinics, clinical research laboratories, and academic institutes. Currently, hospitals and clinics exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global plasma fractionation market include ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd., and Virchow Biotech Private Limited.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Plasma Fractionation Market Report by Product (Immunoglobulins, Albumin, Coagulation factor VIII, Coagulation factor IX), Sector (Private Sector, Public Sector), Application (Neurology, Immunology, Hematology, and Others), End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More